Results 71 to 80 of about 8,545 (210)

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life [PDF]

, 2023
Background. Several drugs which are easy to administer in outpatient settings have been authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to prevent hospital admission and death, complementing COVID-19 vaccines.
Francesca Larese Filon, Luca Cegolon, Omar Simonetti, Riccardo Pol, Roberto Luzzati   +4 more
core   +1 more source

Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to
Sola Akinbolade, Rhiannon Potter, Alex Inskip, Jane Nesworthy, Kirsti Brock, Gill Norman   +5 more
wiley   +1 more source

The Fitness of Molnupiravir-Signed SARS-CoV-2 Variants: Imputation Analysis Based on Prescription Counts and Global Initiative on Sharing All Influenza Data Analyses by Country

Intervirology
Introduction: Molnupiravir is one of the oral direct-acting antivirals against SARS-CoV-2, largely deployed during the COVID-19 pandemic since the 2022 Omicron wave. While efficacy has been questioned in post-marketing clinical trials (leading
Daniele Focosi, Dave McNally, Fabrizio Maggi   +2 more
doaj   +1 more source

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Infectious Diseases and Therapy, 2023
Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for outpatient treatment of mild-to-moderate COVID-19, significantly reducing the risk of ...
Julie M. Strizki, Jay A. Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G. Johnson, Jiejun Du, Patricia Carmelitano, Michelle L. Brown, Amanda Paschke, Carisa De Anda   +9 more
doaj   +1 more source

Successful in vitro propagation of feline coronavirus from clinically diagnosed feline infectious peritonitis cases using Vero cells: A potential model for future research

Veterinary Record Open, Volume 13, Issue 1, June 2026.
Abstract Background Feline coronavirus (FCoV) causes inapparent to progressive fatal feline infectious peritonitis (FIP) in domestic and wild cats, which affects multiple‐organ systems. Methods We investigated three clinically sick cats using different laboratory and molecular tests to diagnose and confirm FCoV and propagate the virus in Vero cell ...
Eaftekhar Ahmed Rana, Mahfuza Akther, Susan Beetson, Subir Sarker, Gabriele Rossi, Jasim M. Uddin   +5 more
wiley   +1 more source

Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19

Биопрепараты: Профилактика, диагностика, лечение, 2022
Finding effective and safe medicines to fight SARS-CoV-2 infection is an urgent task. RPH-137 is an original trap fusion protein against SARS-CoV-2 virus.
E. V. Shipaeva, O. V. Filon, A. V. Zintchenko, G. A. Shipunov, A. A. Dmitrieva, M. S. Lemak, S. A. Grishin, E. I. Trofimets, K. L. Kryshen, L. I. Kozlovskaya, A. S. Lunin, V. D. Apolokhov, S. F. Barbashov, Ya. V. Lavrovsky, M. Yu. Samsonov   +14 more
doaj   +1 more source

Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY [PDF]

, 2023
Objective: To ascertain patient eligibility status and describe coverage of antiviral drugs and neutralising monoclonal antibodies (nMAB) as treatment for covid-19 in community settings in England.
Andrews, Colm D, Bacon, Sebastian CJ, Bates, Christopher, Bhaskaran, Krishnan, Cockburn, Jonathan, Croker, Richard, Curtis, Helen J, Davy, Simon, DeVito, Nicholas J, Dillingham, Iain, Douglas, Ian J, Drysdale, Henry, Evans, David, Evans, Stephen JW, Fisher, Louis, Goldacre, Ben, Green, Amelia, Harper, Sam, Hester, Frank, Hickman, George, Higgins, Rose, Hopcroft, Lisa, Hulme, William J, Inglesham, Peter, MacDonald, Orla, Mackenna, Brian, Mahalingasivam, Viyaasan, Massey, Jonathan, Mehrkar-Asl, Amir-Reza, Morley, Jessica, Morton, Caroline, Nab, Linda, Park, Robin, Parry, John, Rentsch, Christopher T, Smith, Rebecca, Tazare, John, Tomlinson, Laurie A, Walker, Alex J, Wardley, Thomas, Wiedemann, Milan, Zheng, Bang   +41 more
core   +2 more sources

Molnupiravir for treating COVID-19

Cochrane Database of Systematic Reviews
Five years from the start of the COVID-19 pandemic, morbidity and mortality have subsided. Vaccines have contributed to reducing the risk of infection and severe disease. However, new COVID-19 variants continue to emerge, and the role of oral antivirals such as molnupiravir in preventing progression of disease or hospitalisation must be assessed.To ...
Gayle S Tatz, Eleanor A Ochodo, Tilly Fox, Eddy J Owino, Bruce Nyagol, Priscilla Rupali, Michael McCaul, Tamara Kredo, Karen Cohen   +8 more
openaire   +2 more sources

Inhibitors Targeting SARS‐CoV‐2 Papain‐Like Protease: Screening, Design, Synthesis, and Biological Evaluation

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
In our study, we obtained both non‐covalent and covalent PLpro inhibitors. Additionally, the stable protein‐ligand interactions of the active compound were examined using advanced computational docking and molecular dynamics simulations. The non‐covalent inhibitor 2t showed antiviral activity with an EC50 of 2.89 µM, indicating its potential as a ...
Elena‐Oriana Iuga, Nilu Gone, Mariana Ortiz de Godoy, Gabriel Correa Verissimo, Giovanna de Jesus Agostinetto, Liam Urich, Nadine Krüger, Thales Kronenberger, Rafael Victorio Carvalho Guido, Anthony J. O’Donoghue, Stefan A. Laufer, Thanigaimalai Pillaiyar   +11 more
wiley   +1 more source

Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants

Clinical and Translational Science, 2023
Molnupiravir is an orally administered, small‐molecule ribonucleoside prodrug of β‐D‐N4‐hydroxycytidine (NHC) that has demonstrated potent, broad‐spectrum preclinical activity against RNA viruses and has a high barrier to the development of resistance. A
Marian Iwamoto, Kelly E. Duncan, Prachi K. Wickremasingha, Tian Zhao, Maria V. Liberti, Lieselotte Lemoine, Tatjana Decaesteker, Sylvie Rottey, Brian M. Maas, Gillian Gillespie, S. Aubrey Stoch   +10 more
doaj   +1 more source